CAR-T Drugs' Patient-Reported Outcomes To Be Focus Of MedCAC Meeting
Executive Summary
Focus is in line with past US Medicare advisory panel meetings on other diseases.
You may also be interested in...
CAR-T In Medicare: Add-On Payments But No New Bundle Planned For 2019
CMS determines in final hospital inpatient rule that it will reimburse CAR-T drugs under an existing Medicare payment bundle supplemented by add-on payments.
CAR-T Reimbursement Threatened By Medicare Coverage Analysis, Manufacturers Say
Novartis, Gilead/Kite and Celgene protest the US Centers for Medicare and Medicaid Services’ decision to launch a Medicare coverage analysis for CAR-T drugs because it might lead to coverage restrictions.
CAR-T Reimbursement Threatened By Medicare Coverage Analysis, Manufacturers Say
Novartis, Gilead/Kite and Celgene protest the US Centers for Medicare and Medicaid Services’ decision to launch a Medicare coverage analysis for CAR-T drugs because it might lead to coverage restrictions.